Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 6
The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC
Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.
Video content above is prompted by the following:
Treatment Sequencing and One-Line Disease Course
Key Themes:
- Sequential Treatment Planning: Importance of first-line treatment selection given many patients never receive second-line therapy
- Cross-Trial Comparisons: Differences between MARIPOSA and FLAURA2 affecting interpretation and sequencing strategy
- Transition Points: Challenges in ensuring patients remain eligible for subsequent therapy at progression
Notable Insights:
- Dr Piotrowska: Noted that “in some studies up to 40% or so of patients never make it to a second-line therapy,” emphasizing the critical importance of first-line regimen selection.
- Dr Dietrich: Described transition points as “very sobering” and emphasized the need for oncologist involvement when patients progress, noting “with a 71% attrition rate in MARIPOSA, we’re still losing almost 30% of patients” before second-line therapy.
Related Content:
